Drug pipeline
Explore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
NADPH-cytochrome P450 reductase (POR) is an essential membrane-bound flavoprotein located in the endoplasmic reticulum. It serves as the obligatory and sole electron donor for all microsomal (type II) cytochrome P450 (CYP) enzymes, which are responsible for the metabolism of approximately 75% of clinical drugs, as well as endogenous steroids, cholesterol, and fatty acids. POR transfers electrons from NADPH through its FAD and FMN domains to the heme iron of its CYP partners.
In addition to its physiological role in drug clearance and steroidogenesis, POR is a critical target in oncology. It mediates the bioreductive activation of hypoxia-activated prodrugs (HAPs) such as tirapazamine, mitomycin C, and evofosfamide, converting them into cytotoxic species selectively within the hypoxic microenvironment of solid tumors. Genetic mutations in the POR gene lead to cytochrome P450 oxidoreductase deficiency (PORD), which causes disordered steroidogenesis, ambiguous genitalia, and skeletal malformations characteristic of Antley-Bixler syndrome. Consequently, modulating POR activity represents a dual-edged sword, offering therapeutic opportunities in cancer while posing significant risks of endocrine and developmental toxicities.
Bioreductive activation of prodrugs, one-electron reduction, and redox cycling
11 more in the full profile.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Explore the programs pursuing this target and their development progress.
Follow the clinical studies evaluating therapies directed at this target.
Compare approaches across drug candidates, modalities, and indications.
Investigate the research and source evidence behind target biology and development.
Explore patent activity around therapies and technologies addressing this target.
Connect target biology, drug development, and emerging evidence in your research.
See how Gosset can support your research on NADPH-cytochrome P450 reductase (POR).